Generally, the clinical efficacy of tumor immunotherapy is based on the magnitude and ability of T cells to infiltrate and kill tumors, mainly CD8+ T cells.[23] Accordingly, the frequency and killing capacity of tumor antigen‐specific CD8+ T cells induced in vivo are critical for the antitumor effect of tumor vaccines. Here, CD8A is linked to neoplasm.